Supplementary file 1_A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod.docx حسب Yingxiu Wu (22597094)

"…Critically, our comparative analysis suggested a potentially distinct safety profile for etrasimod, such as a more favorable signal for lymphocyte count decreased compared to other S1P modulators.</p>Conclusion<p>This large-scale, updated analysis confirms the established safety profile of etrasimod while providing novel, comparative insights. …"